---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015705"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:34:53.532714+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics reports Q3 net loss of $0.17/share; plans Phase 1b start for GT-02287 by year-end

## Summary
- Net loss per share improved to $0.17 from $0.37 in Q3 2023; R&D spend rose to $2.6M.
- Cash and marketable securities $12M as of Sept 30, 2024, down from $16.8M at Dec 31, 2023.
- Phase 1 MAD results showed 53% increase in GCase activity; safety and tolerability confirmed.
- Initiation of Phase 1b trial in Parkinson's patients expected by end of Q4 2024.
- Pre-IND meeting with FDA planned before end of 2024 to support Phase 2 expansion.

## SEC filing metadata
- accession: 0001558370-24-015705
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837024015705/0001558370-24-015705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837024015705/ganx-20241114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015705
- JSON: https://secwatch.observer/filing/0001558370-24-015705.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.